Intended for healthcare professionals

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Julia Hippisley-Cox, Carol Coupland
Table 1

Characteristics of cases and matched controls. Values are numbers (percentages) unless stated otherwise

CharacteristicCases (n=9218)Controls (n=86 349)
Female3405 (36.9)31 718 (36.7)
Male5813 (63.1)54 631 (63.3)
Median (interquartile range) Townsend score-0.88 (-2.90-2.25)-1.21 (-3.10-1.82)
Median No (interquartile range) of months of prior data87 (63-117)86 (63-117)
Age band (years)
25-3428 (0.3)263 (0.3)
35-44281 (3.0)2800 (3.2)
45-54957 (10.4)9468 (11.0)
55-641812 (19.7)17 900 (20.7)
65-742497 (27.1)24 448 (28.3)
75-842525 (27.4)23 801 (27.6)
≥851118 (12.1)7669 (8.9)
Body mass index (kg/m2)
<305444 (59.1)49 593 (57.4)
≥301593 (17.3)11 903 (13.8)
Not recorded2181 (23.7)24 853 (28.8)
Smoking status
Non-smoker5457 (59.2)52 983 (61.4)
Smoker2550 (27.7)15 709 (18.2)
Not recorded1211 (13.1)17 657 (20.4)
Morbidity before index date
Ischaemic heart disease2639 (28.6)8216 (9.5)
Diabetes1225 (13.3)6188 (7.2)
Hypertension3582 (38.9)25 841 (29.9)
Osteoarthritis1593 (17.3)12 168 (14.1)
Rheumatoid arthritis216 (2.3)1185 (1.4)
Drugs in three years before index date
Statin1787 (19.4)8098 (9.4)
Tricyclic antidepressant1263 (13.7)8570 (9.9)
Selective serotonin reuptake inhibitor832 (9.0)5923 (6.9)
Aspirin3277 (35.6)17 693 (20.5)